Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Next generation lipid lowering drugs, resebidrag, Tyskland

Reference number
Coordinator LIPIGON PHARMACEUTICALS AB
Funding from Vinnova SEK 15 000
Project duration November 2017 - February 2018
Status Completed
Venture Travel grant
Call Travel grant for building international consortia

Purpose and goal

The purpose was to investigate the potential to prepare a Eurostars application between Lipigon, Secarna and Hamburg university. A decision was made to go ahead with the application having Secarna and Lipigon as participants. Secarna will head the application.

Expected effects and result

A positive Eurostars application will render an antisense oligonucleotide drug discovery project, for treatment of dyslipidemia, utilizing the technological expertise of Secarna and the biology knowledge of Lipigon.

Planned approach and implementation

Lipigon visited the two potential partners in Germany and the proposed project was evaluated based on commercial and scientific viability. It was determined that Hamburg University will be a partner that the consortium buys services from to avoid potential IP issues.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 25 November 2019

Reference number 2017-05291

Page statistics